|Calculated MW||28087 Da|
|Purification||Antiserum to TL1A (NT) was raised by repeated immunisation of rabbits with highly purified antigen. Purified IgG was prepared from whole serum by immunoaffinity chromatography.|
|Immunogen||A peptide corresponding to 14 amino acids near the amino terminus of human TL1A.|
|Shelf Life||18 months from the date of despatch.|
|Other Names||Tumor necrosis factor ligand superfamily member 15, TNF ligand-related molecule 1, Vascular endothelial cell growth inhibitor, Tumor necrosis factor ligand superfamily member 15, membrane form, Tumor necrosis factor ligand superfamily member 15, secreted form, TNFSF15, TL1, VEGI|
|Target/Specificity||Rabbit anti-TL1A (N-Terminal) antibody recognizes the amino Terminal of human TL1A, also known as tumour necrosis factor ligand superfamily member 15 (TNFSF15). TL1A acts as a co-stimulator of IFN-gamma secretion through binding to DR3 (death domain receptor 3 or TRAMP) and may play an important role in Th1-mediated diseases such as Crohn’s disease. In cells expressing DR3, TL1A induces NF-kappa-B activation and apoptosis. Decoy receptor 3 (DcR3) is also a receptor for TL1A. DcR3 can apparently neutralise the effect of TL1A, by inhibiting the TL1A-DR3 interaction, thereby inhibiting apoptosis. TL1A is specifically expressed on endothelial cells and is detected on monocytes, placenta, lung, liver, kidney, skeletal muscle, pancreas, spleen, prostate, small intestine and colon.|
|Preservative & Stabilisers||0.02% Sodium Azide (NaN3)|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-TL1A (N-Terminal) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Wen, L. et al. (2003) TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells.J. Biol. Chem. 278: 39251-392582. Bamias, G et al. (2003) Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease.J. Immunol. 171: 4868-48743. Yang, C. R. et al. (2004) Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.Cancer Res. 64: 1122-1129
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.